(Q39626026)

13 September 2017

title

Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus (English)

1 reference

13 September 2017

0 references

0 references

1 reference

Amanda F Dempsey

1

1 reference

13 September 2017

Heidi M Pangborn

series ordinal

2

1 reference

13 September 2017

Lisa A Prosser

series ordinal

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

21 April 2012

1 reference

13 September 2017

1 reference

13 September 2017

volume

30

1 reference

13 September 2017

issue

27

1 reference

13 September 2017

page(s)

4060-4066

1 reference

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Maternal-fetal cytomegalovirus infection: from diagnosis to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Strategies to prevent CMV infection in the neonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

New advances in the diagnosis of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Congenital cytomegalovirus (CMV) epidemiology and awareness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Improving decision analyses: parent preferences (utility values) for pediatric health outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Cost-utility analysis of the cochlear implant in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Teratology: from science to birth defects prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

Assessment of parental acceptance of a potential cytomegalovirus vaccine for adolescent females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.011

10.1016/J.VACCINE.2012.04.011

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference